- ten23 health and BD (Becton, Dickinson and Company) collaborate to develop an RFID-based solution for pre-fillable syringes.
- The RFID system aims to improve traceability and manufacturing efficiency across pharmaceutical production.
ten23 health, a strategic CDMO is collaborating with BD (Becton, Dickinson and Company), a global medical technology company, to enhance aseptic manufacturing through the use of RFID-enabled prefillable syringes. The collaboration seeks to pilot the innovative BD iDFill™ solution, which enhances traceability and process efficiency in pharmaceutical manufacturing.
The new technology equips each PFS with a unique RFID tag known as the Container Unique Identifier (CUID). This allows individual units to be scanned at various stages of production, from filling to packaging, linking vital data such as drug codes, batch numbers, and timestamps. By providing full traceability, the system helps prevent mix-ups, manage investigations, and improve process visibility.
Patrick Jeukenne, president of BD Medical – Pharmaceutical Systems, commented, “BD iDFill™ aims to transform the way we approach quality and efficiency in the fill & finish process by extending the role of the PFS from a drug container to a digital enabler.” ten23 health, which focuses on human-centric and sustainable contract manufacturing, will benefit from this enhanced tracking system.
“We are excited about this collaboration with BD, as it aligns perfectly with our commitment to innovation and quality,” said Hanns-Christian Mahler, CEO of ten23 health.
“This new RFID-based traceability solution has the potential to further enhance our manufacturing processes and also provides signiĆcant beneĆts to our pharmaceutical customers by ensuring greater transparency and reducing risks,” added Andrea Allmendinger, CSO of ten23 health.
Overview of outsourcing trends 
